NurExone Announces Corporate Updates

Executive Summary

• NurExone Biologic Inc. closed a non‑brokered private placement of 1,295,222 units at C$0.68 per unit, raising approximately $880,751 in gross proceeds.
• Each unit includes one common share and one warrant to purchase an additional common share at C$0.85 for up to 36 months, with acceleration provisions if the TSXV price reaches C$1.70.
• The company also announced a consulting agreement with former Bayer scientist Dr. Lars Bärfacker and its finalist status in the 2026 BOLD Awards Healthcare category.

Key Details

• Financing Structure: 1,295,222 units; each unit = 1 common share + 1 warrant.
• Pricing & Proceeds: C$0.68 per unit; aggregate gross proceeds ≈ $880,751 (CAD).
• Warrant Terms: Exercise price C$0.85 per share; term 36 months from closing; acceleration possible if TSXV VWAP ≥ C$1.70 for 20 consecutive trading days, allowing expiry 30 days after notice.
• Use of Proceeds: General working capital purposes to support pre‑clinical programs and milestone roadmap.
• Regulatory Conditions: Closing subject to TSXV approval; securities subject to a statutory hold period of four months and one day.
• Consulting Agreement: Dr. Lars Bärfacker (former Bayer Principal Research Scientist) engaged to advise on European scientific and strategic initiatives.
• Award Recognition: Named finalist in the Healthcare category of the 2026 BOLD Awards; ceremony scheduled for March 27, 2026 in Barcelona, Spain.

Notable Quotes

• “Lars brings many years of experience in the exosome field and a deep understanding of extracellular vesicle biology and its potential therapeutic applications… his perspective will be valuable as NurExone continues advancing its regenerative medicine platform globally, particularly in Europe.” – Dr. Lior Shaltiel, CEO
• “This financing strengthens our preclinical programs and advances the Company along its milestone‑based roadmap.” – Eran Ovadya, CFO